Policisztás vesebetegség: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PKD1 1
• SGLT2 1
• CFTR 1
• AMPK 1
• STAT3 0
• GLP-1 1
• mTOR 0
• MUC1 0
• CDK4/6 0
• DMD 1
• EGFR 0
• G6PD 0
• HER2 0
• HTT 1
• IL-6 0
• MAPK 0
• NF1 1
• NRF2 1
• PD-L1 0
• PKM2 0
• PPAR 0
• SMN1 1
• STING 0
• TLR4 0
• TNF 0
• YAP 0

255 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting Glutamine (Q) Metabolism in the Renal Ciliopathies (QrCiliopathies)

  Ospedale San Raffaele Srl· Milano, Olaszország· EU contribution 150 000 EUR· until 2028. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Advancing genetic medicines for inherited kidney disease (RENALGENE)

  Fundacion Para la Investigacion Medica Aplicada Fima· Pamplona, Spanyolország· EU contribution 1 500 000 EUR· until 2031. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  A Novel Glutamine (Q) Sensory Role for Primary Cilia: Implications for Health and Disease (QtCilia)

  Ospedale San Raffaele Srl· Milano, Olaszország· EU contribution 2 500 000 EUR· until 2029. okt.

3 of 3 running projects, newest first. Listed amounts together: 4,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

  NCT07228364· AstraZeneca· Forrás

• Bempedoic Acid Therapy for Polycystic Kidney Disease

  NCT07282821· Kenneth Hallows· Forrás

• A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

  NCT06734234· GlaxoSmithKline· Forrás

• Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

  NCT05510115· University of Colorado, Denver· Forrás

• Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository

  NCT03901521· Weill Medical College of Cornell University· Forrás

• Canadian Medical Assessment of JINARC™ Outcomes Registry

  NCT02925221· Otsuka Canada Pharmaceutical Inc.· Forrás

• Daily Caloric Restriction in ADPKD

  NCT04907799· University of Colorado, Denver· Forrás

• Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

  NCT06582875· University of Colorado, Denver· Forrás

• A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 12 weeks of Age with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

  NCT04786574· Otsuka Pharmaceutical Development & Commercialization Inc.· Forrás

• Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease

  NCT06036992· University Hospital, Brest· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 2
• Organoids 3
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 7
• Gene Expression Profiling 4
• Whole Genome Sequencing 2
• Exome Sequencing 9
• Metabolomics 1
• Immunohistochemistry 1
• Magnetic Resonance Imaging 10
• Machine Learning 2
• Deep Learning 4
• Cohort Studies 13
• Genome-Wide Association Study 2

• Genetic Spectrum and Family-Based Cascade Screening in Vietnamese Families With Autosomal Dominant Polycystic Kidney Disease.

  Nephrology (Carlton), 2026. okt.

• Exome sequencing in patients with medullary sponge kidney.

  Nephrol Dial Transplant, 2026. szept.

• A novel PKHD1 missense variant disrupting splicing in a fetus with Caroli disease.

  Gene, 2026. aug.

• Compound heterozygous mutations in CC2D2A cause Meckel-Gruber syndrome: a case report and review of the literature.

  J Med Case Rep, 2026. máj.

• Prevalence and Genetic Spectrum of Inherited Kidney Diseases: A Chinese Cohort Study.

  Kidney360, 2026. ápr.

• Optimizing next-generation sequencing for genetic diagnosis in autosomal dominant polycystic kidney disease.

  Genet Med, 2026. febr.

• Exome Sequencing in a Large Cohort with Ciliopathy-Related Kidney Disease.

  Clin J Am Soc Nephrol, 2025. dec.

• Atypical presentations of fetal polycystic kidney disease demonstrates the utility of a genomic autopsy for accurate post-mortem diagnoses.

  Hum Genomics, 2025. nov.

• Whole-exome sequencing of kidney transplant recipients and donors: insights into end-stage renal disease and post-transplant genetic risk.

  BMC Nephrol, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.